Suppr超能文献

按假释和缓刑状态划分的非裔美国丁丙诺啡患者的治疗结果

Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.

作者信息

Mitchell Shannon Gwin, Gryczynski Jan, Kelly Sharon M, O'Grady Kevin E, Jaffe Jerome H, Olsen Yngvild K, Schwartz Robert P

机构信息

Friends Research Institute, Baltimore, MD 21201 USA.

University of Maryland, College Park, Department of Psychology College Park, MD 20742 USA.

出版信息

J Drug Issues. 2014 Jan;44(1):69-82. doi: 10.1177/0022042613491106.

Abstract

This secondary analysis compared outcomes of African-American adults newly-admitted to buprenorphine treatment who were on parole and probation to patients who were not under criminal justice supervision. Buprenorphine patients (N=300) were randomly assigned to receive either Intensive Outpatient Treatment (IOP) or Standard Outpatient Treatment (OP) treatment and were assessed at baseline, 3- and 6-months. There were no differences between groups in treatment retention. Among probationers/parolees, IOP was associated with lower 3-month treatment retention compared to OP, but among participants not on probation/parole the relationship was reversed (=.004). Both conditions showed significant declines in heroin and cocaine use, illegal activity, and in meeting DSM-IV criteria for opioid and cocaine dependence. Probationers/parolees reported lower frequency of illegal activities at 3-months compared to non-probationers/parolees (=.007). Buprenorphine treatment should be made more widely available to individuals on parole/probation as they respond as well to treatment as patients not supervised by the criminal justice system.

摘要

这项二次分析比较了新接受丁丙诺啡治疗的非裔美国成年假释和缓刑患者与未受刑事司法监管患者的治疗结果。丁丙诺啡治疗患者(N = 300)被随机分配接受强化门诊治疗(IOP)或标准门诊治疗(OP),并在基线、3个月和6个月时进行评估。两组在治疗保留率方面没有差异。在缓刑/假释人员中,与OP相比,IOP与3个月治疗保留率较低相关,但在未缓刑/假释的参与者中,这种关系则相反(P =.004)。两种治疗条件下,海洛因和可卡因使用、非法活动以及符合DSM-IV阿片类药物和可卡因依赖标准的情况均有显著下降。与未缓刑/假释人员相比,缓刑/假释人员在3个月时报告的非法活动频率较低(P =.007)。应使假释/缓刑人员更广泛地获得丁丙诺啡治疗,因为他们对治疗的反应与未受刑事司法系统监管的患者一样良好。

相似文献

1
Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.
J Drug Issues. 2014 Jan;44(1):69-82. doi: 10.1177/0022042613491106.
2
3
A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment.
Contemp Clin Trials. 2019 Apr;79:21-27. doi: 10.1016/j.cct.2019.02.009. Epub 2019 Feb 20.
4
A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans.
Drug Alcohol Depend. 2013 Mar 1;128(3):222-9. doi: 10.1016/j.drugalcdep.2012.08.027. Epub 2012 Sep 20.
5
Buprenorphine Treatment for Probationers and Parolees.
Subst Abus. 2015;36(2):217-25. doi: 10.1080/08897077.2014.902787. Epub 2014 Apr 4.
7
Rapid HIV testing for individuals on probation/parole: outcomes of an intervention trial.
AIDS Behav. 2013 Jul;17(6):2022-30. doi: 10.1007/s10461-013-0456-6.
8
The metropolitan context of substance use and substance use disorders among US adults on probation or parole supervision.
Subst Abus. 2022;43(1):161-170. doi: 10.1080/08897077.2021.1903651. Epub 2021 Apr 13.
9
Research on naltrexone in the criminal justice system.
J Subst Abuse Treat. 2006 Sep;31(2):113-5. doi: 10.1016/j.jsat.2006.06.021. Epub 2006 Aug 2.
10
Mental health treatment among older adults with mental illness on parole or probation.
Health Justice. 2019 Mar 28;7(1):4. doi: 10.1186/s40352-019-0084-y.

引用本文的文献

1
Relapses in Illicit Drug Use Among Probationers: Results in a Risk Group of Public Health Services in Bavaria.
Int J Public Health. 2023 Oct 11;68:1605955. doi: 10.3389/ijph.2023.1605955. eCollection 2023.
2
Does incarceration influence patients' goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail.
Drug Alcohol Depend. 2021 May 1;222:108529. doi: 10.1016/j.drugalcdep.2021.108529. Epub 2021 Mar 18.
4
Interventions for female drug-using offenders.
Cochrane Database Syst Rev. 2019 Dec 13;12(12):CD010910. doi: 10.1002/14651858.CD010910.pub3.
5
Interventions for drug-using offenders with co-occurring mental health problems.
Cochrane Database Syst Rev. 2019 Oct 7;10(10):CD010901. doi: 10.1002/14651858.CD010901.pub3.
6
Pharmacotherapy for opioid addiction in community corrections.
Int Rev Psychiatry. 2018 Oct;30(5):117-135. doi: 10.1080/09540261.2018.1524373. Epub 2018 Dec 6.
7
Italian psychiatry.
Int Rev Psychiatry. 2018 Apr;30(2):117. doi: 10.1080/09540261.2018.1435761.
8
Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients.
Subst Abus. 2017 Jul-Sep;38(3):297-302. doi: 10.1080/08897077.2016.1220443. Epub 2016 Aug 11.

本文引用的文献

1
Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.
Am J Public Health. 2013 May;103(5):917-22. doi: 10.2105/AJPH.2012.301049. Epub 2013 Mar 14.
2
3
A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans.
Drug Alcohol Depend. 2013 Mar 1;128(3):222-9. doi: 10.1016/j.drugalcdep.2012.08.027. Epub 2012 Sep 20.
6
Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings.
Addiction. 2012 May;107(5):943-52. doi: 10.1111/j.1360-0443.2011.03700.x. Epub 2012 Feb 11.
8
Patterns in admission delays to outpatient methadone treatment in the United States.
J Subst Abuse Treat. 2011 Dec;41(4):431-9. doi: 10.1016/j.jsat.2011.06.005. Epub 2011 Aug 6.
9
Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system.
Drug Alcohol Depend. 2011 Dec 15;119(3):172-8. doi: 10.1016/j.drugalcdep.2011.06.021. Epub 2011 Jul 23.
10
Buprenorphine-naloxone Treatment for Pre-release Opioid-dependent Inmates in Puerto Rico.
J Addict Med. 2007 Sep;1(3):126-32. doi: 10.1097/ADM.0b013e31814b8880.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验